Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs

Q3 Revenue Rises Despite Pandemic’s Impacts On Vaccines Business

 
• By Mandy Jackson

Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.

old chronometer
Merck& Co.'s COVID-19 programs are not the fastest in the clinic but may have oral or one-time dosing advantages

More from Earnings

More from Business